Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106


Spectrum of Radiopharmaceuticals in Nuclear Oncology

Author(s): Delphine Denoyer, Nathalie Perek, Nathalie L. Jeune, Francis Dubois.


A major field of interest in nuclear medicine is in vivo tumor characterization and measurement of biological processes at cellular and molecular levels by means of positron emission tomography (PET) or single photon emission computed tomography (SPECT). Functional imaging with radiopharmaceuticals represents a useful noninvasive tool to evaluate the biological status of the tumor and its progression. The properties of radiopharmaceuticals are exploited for initial staging of cancer, assessment of recurrent or residual disease and, more recently, considerable progress has been made in the field of the evaluation of tumor response to treatment. PET and SPECT can both detect changes in tumor activity caused by therapy or disease progression before any detectable change in tumor volume. Measurement of tumor response to therapy using PET and SPECT is the subject of intense investigations because it may result in individualization of treatment and may have a prognostic value for long-term outcome. This review focuses on the various methods used to monitor anticancer therapy with a variety of clinically approved or investigational tracers. We summarize the mechanisms of radiopharmaceutical uptake based on certain physiological activities affected by treatment: proliferation, apoptosis, hypoxia, angiogenesis and multidrug resistance (MDR).

Keywords: Tumor imaging, PET, SPECT, cell proliferation, apoptosis, multidrug resistance, hypoxia, angiogenesis

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2006
Page: [181 - 196]
Pages: 16
DOI: 10.2174/156800906776842984
Price: $58